ロード中...
Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab
In selected patients with moderate to severe active ulcerative colitis who have failed to respond or are poorly responsive to standard pharmacologic forms of treatment with corticosteroids and immunosuppressive agents, therapy with a biological agent may be considered. While infliximab is an establi...
保存先:
| 第一著者: | |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3826758/ https://ncbi.nlm.nih.gov/pubmed/24235838 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S38852 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|